Press and Announcements

Praetego’s progress is routinely updated as we strive to enter clinical trials.
Please check back frequently for news, announcements, and events.



ipeline Praetego’s Amadorins have demonstrated preclinical proof of efficacy in Alzheimer’s disease and Diabetic Peripheral Neuropathy. We have two candidates under development, lead PTG-630 and PTG-670. Our Alzheimer’s Disease program leads the pipeline and is complemented by our efforts in Diabetic Peripheral Neuropathy and Diabetic Retinopathy. Read More >